Codon-Altered Factor IX Gene Therapy for Hemophilia B
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia B, such as Factor IX replacement therapy, are costly, require frequent administration, and can lead to the formation of anti-Factor IX inhibitor antibodies, with no existing bypass therapies available, necessitating a more effective and sustainable solution.
Innovation Solution
Development of codon-altered nucleic acids encoding Factor IX proteins that are more efficiently expressed and delivered via adeno-associated virus (AAV) gene therapy vectors, with improved folding properties and activity, allowing for increased production and reduced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor IX replacement therapy is administered frequently to maintain therapeutic levels, then bleeding episodes are prevented, but treatment cost and patient burden increase significantly
Solution Approach 1:
The patent applies preliminary action by using AAV gene therapy to deliver the Factor IX gene to hepatocytes before bleeding episodes occur. The transduced cells continuously produce Factor IX protein, establishing a sustained therapeutic effect that eliminates the need for repeated administrations. This preliminary genetic modification provides long-term protection against bleeding without requiring frequent treatment interventions.
2Reliability
If conventional Factor IX products are used, then short-term clotting function is restored, but the therapy requires repeated administrations due to short half-life
Solution Approach 1:
The patent applies self-service by enabling the patient's own liver cells to produce Factor IX protein autonomously after AAV transduction. The hepatocytes that receive the therapeutic gene continue to synthesize and secrete functional Factor IX on their own, maintaining therapeutic levels without requiring external administration. This self-sustaining production mechanism extends the duration of action from hours to years.
3Reliability
If high doses of Factor IX are administered to achieve therapeutic levels, then clotting function is improved, but formation of anti-Factor IX inhibitor antibodies increases
Solution Approach 1:
The patent applies parameter changes by modifying the delivery mechanism and kinetics of Factor IX production. Instead of sudden high-dose administrations that trigger immune responses, the AAV gene therapy establishes gradual, sustained production of Factor IX at physiological levels. The transduced hepatocytes secrete Factor IX continuously over time, maintaining therapeutic concentrations without the sharp peaks that induce inhibitor antibody formation.
Data Source
AI summary
The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.